A Meta-analysis on influence of Alirocumab on clinical cardiovascular events
Zhu Yuhan
Shen Xiaoxu
Wang Zhen
Li Jiebai
Abstract：Objective To systematic review the influence of Alirocumab on clinical cardiovascular events. Methods The databases of PubMed, The Cochrane Library (volume 1, 2017), EMbase, Web of Science, CBM, WanFang Data, VIP and CNKI were retrieved with computer for searching the randomized controlled trials (RCT) related to the influence of Alirocumab on clinical cardiovascular events. The retrieving time was from database establishment time to May 2017, and retrieving methods combined MeSH subject terms and free terms. The data was given a Meta-analysis by using Stata 12.0 software. Results There were finally 9 RCT included involved 4799 patients, and 3123 in Alirocumab group and 1676 in control group. The statistical results showed that cardiac death rate was significantly decreased in Alirocumab group (RR=0.36, 95%CI: 0.14~0.93, P=0.035) compared with control group. While the difference in incidence of myocardial infarction, coronary revascularization and stroke, admission rate due to unstable angina pectoris and total incidence of clinical cardiovascular events had no statistical significance (P>0.05). Conclusion Alirocumab can reduce cardiac death rate, but has no significant superiority in reducing incidence of myocardial infarction, coronary revascularization and stroke, admission rate due to unstable angina pectoris and total incidence of clinical cardiovascular events. More RCT with higher quality are needed to further verify the above conclusion.
Keywords：AlirocumabCardiovascular eventsMeta-analysisRandomized controlled trial
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 155-158,163 )